Leerink Partnrs Estimates Sanofi’s Q3 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Sanofi in a report issued on Monday, January 27th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of $1.57 for the quarter. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2025 earnings at $0.91 EPS and FY2029 earnings at $5.88 EPS.

Separately, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Price Performance

SNY opened at $52.97 on Wednesday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm has a 50-day moving average of $48.90 and a 200 day moving average of $52.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $134.43 billion, a P/E ratio of 27.03, a PEG ratio of 1.19 and a beta of 0.57.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in Sanofi by 0.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock valued at $15,466,000 after acquiring an additional 1,238 shares during the period. AQR Capital Management LLC purchased a new stake in Sanofi during the 2nd quarter worth about $344,000. The Manufacturers Life Insurance Company grew its holdings in Sanofi by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company’s stock valued at $1,530,000 after buying an additional 6,756 shares in the last quarter. Creative Planning increased its position in shares of Sanofi by 9.2% during the second quarter. Creative Planning now owns 187,035 shares of the company’s stock valued at $9,075,000 after buying an additional 15,749 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in shares of Sanofi by 27.2% in the second quarter. NewEdge Advisors LLC now owns 29,587 shares of the company’s stock worth $1,436,000 after buying an additional 6,330 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.